Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 6/2015

01-06-2015 | Original Article

Axial spondyloarthritis: the heart of the matter

Author: Lianne S. Gensler

Published in: Clinical Rheumatology | Issue 6/2015

Login to get access

Abstract

A variety of cardiovascular clinical manifestations have been described in patients with spondyloarthritis, especially in well-established ankylosing spondylitis. These include both structural heart disease, conduction defects and ischemic heart disease. The true prevalence of cardiovascular involvement in patients with axial spondyloarthritis, including non-radiographic disease needs to be further defined.
Literature
1.
2.
Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 52:402–411CrossRefPubMed
3.
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732CrossRefPubMed
4.
5.
Ogdie G, Yiding Y, Haynes K et al (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74:326–332CrossRefPubMed
6.
Gensler LS, Ward MM, Lee MJ, Rahbar M, Brown MA, Reveille JD et al (2013) Cardiovascular disease is associated with worse functional outcomes in ankylosing spondylitis. [abstract]. Arthritis Rheum 65(Suppl 10):2448
7.
Heslinga SC, Van Dongen CJ, Konings TC, Peters MJ, Van der Horst-Bruinsma IE, Smulders YM, Nurmohamed MT (2014) Diastolic left ventricular dysfunction in ankylosing spondylitis—a systematic review and meta-analysis. Semin Arthritis Rheum 44(1):14–19CrossRefPubMed
8.
Mathieu S, Gossec L, Dougados M, Soubrier M (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 63:557–563. doi:10.​1002/​acr.​20364 CrossRef
9.
Bremander A, Petersson IF, Bergman S, Englund M (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 63:550–556. doi:10.​1002/​acr.​20408 CrossRef
10.
van Halm VP, Van Denderen JC, Peters MJ, Twisk JW, Van Der Paardt M, Van Der Horst-Bruinsma IE et al (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65:1473–1477CrossRefPubMedCentralPubMed
11.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [published erratum appears in JAMA 2005;294:3092]. JAMA 294:2437–2445CrossRefPubMed
12.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMed
13.
Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun C-C, LaRosa JC, Betteridge J, Pedersen TR, Holme I (2012) Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 64:2836–2846. doi:10.​1002/​art.​34524 CrossRefPubMed
14.
Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M, Maksymowych WP (2011) Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 63:3294–3304. doi:10.​1002/​art.​30581 CrossRefPubMed
15.
Brophy S, Cooksey R, Atkinson M, Zhou S-M, Husain MJ, Macey S, Rahman MA, Siebert S (2012) No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis—a retrospective cohort study using routine data. Semin Arthritis Rheum 42(2):140–145CrossRefPubMed
16.
Huang Y-P, Wang Y-H, Pan S-L (2013) Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis—a population-based longitudinal follow-up study. Kuwana M, ed. PLoS ONE. 8(5):e64155. doi:10.​1371/​journal.​pone.​0064155.
17.
Lin C-W, Huang Y-P, Chiu Y-H, Ho Y-T, Pan S-L (2014) Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. Rosenbaum JT, ed. PLoS ONE. 9(4):e94027. doi:10.​1371/​journal.​pone.​0094027.
18.
Keller JJ, Hsu J-L, Lin S-M, Chou C-C, Wang L-H, Wang J, Bai C-H, Chiou H-Y (2014) Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study. Rheumatol Int 34(2):255–263CrossRefPubMed
19.
Graham DC, Smythe HA (1958) The carditis and aortitis of ankylosing spondylitis. Bull Rheum Dis 9:171–174PubMed
20.
Bergfeldt L, Insulander P, Lindblom D, Moller E, Edhag O (1988) HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med Vol 85(1):12–18CrossRef
21.
22.
Bergfeldt LHLA (1982) B27-associated rheumatic diseases with severe cardiac Bradyarrhythmias. Am J Med 73:187–191CrossRefPubMed
23.
Bergfeldt L, Möller E (1983) Complete heart block—another HLA B27 associated disease manifestation. Tissue Antigens 21(5):385–390CrossRefPubMed
24.
Bergfeldt L, Vallin H, Edhag O (1984) Complete heart block in HLA B27 associated disease. Electrophysiological and clinical characteristics. Br Heart J 51(2):184–188CrossRefPubMedCentralPubMed
25.
Peeters AJ, ten Wolde S, Sedney MI, de Vries RRP, Dijkmans BAC (1991) Heart conduction disturbance: an HLA B27 associated disease. Ann Rheum Dis 50:348–350CrossRefPubMedCentralPubMed
26.
27.
Dik VK, Peters MJL, Dijkmans PA, Van der Weijden MAC, De Vries MK, Dijkmans BAC, Van der Horst-Bruinsma IE, Nurmohamed MT (2010) The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol 39:38CrossRefPubMed
28.
29.
30.
Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF (2011) Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 63:1182–1189. doi:10.​1002/​art.​30277 CrossRefPubMed
31.
32.
Capkin E, Karkucak M, Kiris A, Durmus I, Karaman K, Karaca A, Tosun M, Ayar A (2012) Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 51(5):910–914. doi:10.​1093/​rheumatology/​ker434, first published online January 16, 2012 CrossRefPubMed
33.
Mathieu S, Pereira B, Couderc M, Rabois E, Dubost J-J, Soubrier M (2012) No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology. doi:10.​1093/​rheumatology/​kes272
34.
Peters MJ (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory. Arthritis Ann Rheum Dis 69:325–331CrossRef
Metadata
Title
Axial spondyloarthritis: the heart of the matter
Author
Lianne S. Gensler
Publication date
01-06-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-2959-1

Other articles of this Issue 6/2015

Clinical Rheumatology 6/2015 Go to the issue

Original Article

A cross-sectional survey assessing sources of movement-related fear among people with fibromyalgia syndrome

Editorial

SPARTAN annual meeting, New York City 2014

Review

Ankylosis in ankylosing spondylitis: current concepts

Original Article

Clinical features and types of articular involvement in patients with psoriatic arthritis

Original Article

Sexual function in Moroccan women with rheumatoid arthritis and its relationship with disease activity

Case Based Review

Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits